Nitrogen Containing Compound Doai Patents (Class 514/740)
  • Patent number: 11141387
    Abstract: An external preparation containing memantine which has less skin irritation and excellent skin permeability, and also, which is suitable for continuous administration for a long period of time. The external preparation contains memantine or a salt thereof, and further contains 0.05 to 1.5% by weight of phosphatidylcholine, 35 to 55% by weight of propylene glycol, 18 to 30% by weight of glycerine, and 22 to 32% by weight of water. The content of water less than 22% by weight may increase skin irritation, and the content of water more than 32% by weight may decrease skin permeability. The content of glycerin less than 18% by weight may increase skin irritation, and the content of glycerin more than 30% by weight may decrease skin permeability.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: October 12, 2021
    Assignee: MEDRX CO., LTD.
    Inventor: Keiko Yamasaki
  • Patent number: 9963463
    Abstract: The present invention relates to novel indanyl urea derivatives of formula (I): their pharmaceutically acceptable salts, and their isomers, steroisomers, atropisomers, conformers, tautomers, polymorphs, hydrates and solvates. The present invention also encompasses process for preparing novel compounds and pharmaceutical composition of said compounds. The invention further relates to the use of the compounds for the preparation of medicament for use as pharmaceuticals.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: May 8, 2018
    Assignee: Torrent Pharmaceuticals Limited
    Inventors: Milind Rode, Sanjay Srivastava, Davindar Tuli, Deepak Rai, Prashant Gj, Shailesh Deshpande, Rameshchandra Gupta, Vijay Chauthaiwale, Chaitanya Dutt
  • Patent number: 9248117
    Abstract: The present application describes compounds of Formula I: which are antimicrobial agents, including antibacterial, disinfectant, antifungal, germicidal and/or antiviral agents.
    Type: Grant
    Filed: October 18, 2011
    Date of Patent: February 2, 2016
    Inventors: Rakesh K. Jain, Timothy Shiau, Charles Francavilla, Eddy Low, Eric Douglas Turtle, Donogh John Roger O'Mahony
  • Patent number: 9029503
    Abstract: The invention mainly relates to a method for manufacturing a polypeptide of formula: X1—X?—X2??(III) X1 and X2 each representing a peptide fragment, and X? representing an amino acid residue comprising a thiol function, said method comprising at least one step of ligation reaction between a polypeptide of formula: X1—N(CH2CH2SH)2??(I) and a polypeptide of formula: H—X?—X2.??(II) The invention also relates to the polypeptides of formula (I) themselves and the method for obtaining them, as well as resin supports suitable for obtaining them.
    Type: Grant
    Filed: October 28, 2010
    Date of Patent: May 12, 2015
    Assignees: Centre National de la Recherche Scientifique, Institut Pasteur de Lille
    Inventors: Oleg Melnyk, Reda Mhidia, Julien Dheur, Nathalie Ollivier
  • Publication number: 20150111973
    Abstract: The present invention relates to methods of treating steroid hormone related disorders by modulating steroid hormone activity.
    Type: Application
    Filed: February 28, 2013
    Publication date: April 23, 2015
    Applicant: Novan, Inc.
    Inventors: Susanne Bauman, William Reed Kelce
  • Publication number: 20150105475
    Abstract: The present disclosure relates to devices and methods for the preparation of amyl nitrite formulations at a point of use location from relatively shelf-stable reagents employing acidic cationic exchange resins.
    Type: Application
    Filed: October 15, 2013
    Publication date: April 16, 2015
    Inventors: Joseph A. McDONOUGH, Darrel W. JOHNSTON, Paul M. THOMPSON
  • Publication number: 20150105474
    Abstract: The present invention is directed at isoamyl nitrite formulations suitable for use in medicinal applications. The formulations include a composition of isoamyl nitrite in combination with an epoxidized vegetable oil, identified as stabilized isoamyl nitrite. The isoamyl nitrite may also be combined with petrolatum. Methods of treatment of the formulations are applicable to cyanide poisoning, H2S poisoning as well as treatment for elevated blood pressure.
    Type: Application
    Filed: October 15, 2013
    Publication date: April 16, 2015
    Inventors: Albert M. ZWIENER, Kenneth H. CARSON, Joseph A. McDONOUGH, Larry A. CABELL, Norma L. CANTU, Sandra J. DRABIK, Andrew P-Z. CLARK, Paul M. THOMPSON, Richard Michael CORBETT
  • Patent number: 8993639
    Abstract: The invention relates to the use of a L-theanine for the treatment of gastroesophageal reflux disease (e.g., heartburn) in a human or animal, including useful methods and compositions.
    Type: Grant
    Filed: March 20, 2009
    Date of Patent: March 31, 2015
    Inventors: Burt Shulman, Barrie R. Froseth, Ravindranath S. Menon
  • Patent number: 8993631
    Abstract: The present invention provides the use of a neutral endopeptidase inhibitor, in the manufacture of a medicament for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The invention also relates to the use of a compound of Formula I: wherein R1, R2, R3, R5, X, A3, B1, s and n are defined herein, for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The present invention further provides a combination of pharmacologically active agents for use in the treatment, amelioration and/or prevention of contrast-induced nephropathy.
    Type: Grant
    Filed: November 11, 2011
    Date of Patent: March 31, 2015
    Assignee: Novartis AG
    Inventor: Shi Yin Foo
  • Patent number: 8992991
    Abstract: Degradable polymers were synthesized that self-assemble with DNA to form particles that are effective for gene delivery. Small changes to polymer synthesis conditions, particle formulation conditions, and polymer structure provides significant changes to efficacy in a cell-type dependent manner. Polymers presented here are more effective than commercially available materials, such as LIPOFECTAMINE 2000™, FUGENE®, or polyethylenimine (PEI), for gene delivery to cancerous fibroblasts or human primary fibroblasts. The presently disclosed materials may be useful for cancer therapeutics and regenerative medicine.
    Type: Grant
    Filed: May 17, 2010
    Date of Patent: March 31, 2015
    Assignee: The Johns Hopkins University
    Inventors: Jordan J. Green, Joel C. Sunshine, Nupura S. Bhise, Ron B. Shmueli, Stephany Y. Tzeng
  • Patent number: 8993640
    Abstract: The present invention relates generally to the compound: N-((4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicen-4a-yl)-2,2-difluoropropanamide, polymorphic forms thereof, methods for preparation and use thereof, pharmaceutical compositions thereof, and kits and articles of manufacture thereof.
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: March 31, 2015
    Assignee: Reata Pharmaceuticals, Inc.
    Inventors: Eric Anderson, Xiaofeng Liu, Andrea Decker
  • Patent number: 8969297
    Abstract: Provided herein are methods for the induction of hypothermia and the treatment of clinical insults in a subject through the administration of a regulated hypothermic multidrug combination. The compositions or multidrug combinations of the invention comprise a regulated hypothermic compound or a dopamine receptor agonist; a vasoactive compound; and an antiarrhythmic compound or a serotonin 5-HT3 receptor antagonist. Additional agents can be included in the composition including at least one of an antioxidant, a vitamin, N-acetylcysteine, and an antihyperglycemic compound. The invention further recognizes that a two phase delivery of multidrug combinations, a rapid infusion of the composition to induce hypothermia followed by a period of slow infusion to maintain the hypothermic state for a sustained period of time.
    Type: Grant
    Filed: June 9, 2010
    Date of Patent: March 3, 2015
    Assignee: The University of North Carolina at Chapel Hill
    Inventor: Laurence M. Katz
  • Patent number: 8952057
    Abstract: Compositions containing polymetal complexes are useful in treating anorectal disorders.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: February 10, 2015
    Assignee: JR Chem, LLC
    Inventor: José E. Ramirez
  • Patent number: 8946474
    Abstract: The present invention relates to the crystalline, polymorphic Form X of the calcimimetic compound {4-[(1R,3S)-3-((R)-1-Naphthalen-1-yl-ethylamino)-cyclopentyl]-phenoxy}-acetic acid, to methods of preparation thereof, to methods of characterization thereof by single crystal X-Ray crystallography (XRC), X-Ray Powder diffractometry, attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectroscopy, Solid State NMR spectroscopy and Differential Scanning Calorimetry (DSC), and to its use. The invention also relates to the preparation of Form X by crystallization from a saturated solution of {4-[(1R,3S)-3-((R)-1-Naphthalen-1-yl-ethylamino)-cyclopentyl]-phenoxy}-acetic acid in a C1-C6 alkyl alcohol, or alternatively by precipitation from a neutralized saponification reaction mixture following the alkaline hydrolysis of a C1-C6 alkyl ester of {4-[(1R,3S)-3-((R)-1-Naphthalen-1-yl-ethylamino)-cyclopentyl]-phenoxy}-acetic acid.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: February 3, 2015
    Assignee: LEO Pharma A/S
    Inventors: Søren Ebdrup, Kim Troensegaard Nielsen, Tanja Maria Greve
  • Patent number: 8940798
    Abstract: The present invention concerns a method for treating and/or preventing a disease in a subject comprising the step of administrating an effective amount of a compound of formula I to a subject in need thereof.
    Type: Grant
    Filed: November 5, 2012
    Date of Patent: January 27, 2015
    Assignees: Centre National de la Recherche Scientifique (CNRS), Universite Montpellier 2 Sciences et Techniques
    Inventor: Anne Blangy
  • Patent number: 8889738
    Abstract: Compounds, polymers, crosslinked polymers and pharmaceutical compositions comprising the same may be derived from multi-amine monomers and multi-functional monomers having two or more amine reactive groups. Such compounds, polymers, crosslinked polymers and compositions may be used to treat hyperphosphatemia or to remove ions from the gastrointestinal tract of animals, including humans.
    Type: Grant
    Filed: March 12, 2012
    Date of Patent: November 18, 2014
    Assignee: Genzyme Corporation
    Inventors: Pradeep K. Dhal, Stephen Randall Holmes-Farley, Chad C. Huval
  • Patent number: 8889657
    Abstract: The present invention provides phosphonate conjugates and methods of preparing the phosphonate conjugates so as to allow, for example, improved methods and compounds for modifying the surface of a nanoparticle to increase in vivo circulation times and targeted delivery performance.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: November 18, 2014
    Assignee: Mallinckrodt LLC
    Inventor: Thomas E. Rogers
  • Patent number: 8865776
    Abstract: The use of low molecular weight amino alcohols in ophthalmic compositions is described. These compounds have been found to enhance the efficacy of anti-microbial preservatives.
    Type: Grant
    Filed: September 18, 2013
    Date of Patent: October 21, 2014
    Assignee: Alcon Research, Ltd.
    Inventor: Bahram Asgharian
  • Patent number: 8859627
    Abstract: The present invention relates to an anti-microbial composition and method of use thereof. In particular, the present invention relates to an anti microbial composition comprising farnesol and cetrimide.
    Type: Grant
    Filed: October 23, 2008
    Date of Patent: October 14, 2014
    Assignee: Wild Child
    Inventor: John Found
  • Patent number: 8853281
    Abstract: Compounds of the formula I wherein R1a is H; and R1b is C1-C6 alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R2b are H, halo, C1-C4alkyl, C1-C4haloalkyl, C1-C4alkoxy; or R2a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl; R3 is a branched C5-C10alkyl chain, C2-C4haloalkyl or C3-C7cycloalkylmethyl, R4 is Het, Carbocyclyl, optionally substituted as defined in the specification and pharmaceutically acceptable salts, hydrates and N-oxides thereof; are inhibitors of cathepsin S and have utility in the treatment of psoriasis, autoimmune disorders and other disorders such as asthma, arteriosclerosis, COPD and chronic pain.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: October 7, 2014
    Assignee: Medivir UK Ltd
    Inventors: Susana Ayesa, Anna Karin Belfrage, Bjorn Classon, Urszula Grabowska, Ellen Hewitt, Vladimir Ivanov, Daniel Jönsson, Pia Kahnberg, Peter Lind, Magnus Nilsson, Lourdes Odén, Mikael Pelcman, Horst Wähling
  • Patent number: 8822489
    Abstract: This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: September 2, 2014
    Assignee: Acura Pharmaceuticals
    Inventors: Vijai Kumar, David Dixon, Divya Tewari, Dilip B. Wadgaonkar
  • Patent number: 8785504
    Abstract: A compound of the general formula (I) is provided for use in the topical treatment of infection, inflammation and/or pain: wherein R1 independently represents a methylene group, an ethylene group or a straight or branched chain C3 to C6 alkylene group; R2 independently represents a hydrogen atom, a methyl group, an ethyl group or a straight or branched chain C3 to C20 alkyl group; x represents 0 or an integer from 1 to 4 and y represents 0 or an integer from 1 to 4, wherein the sum of x and y is 4; and Z represents a hydrogen atom or (HOR1)yR2xN+; compositions including the compound; use of the compound in the manufacture of a medicament; and methods of medical treatment including the topical application of the compound.
    Type: Grant
    Filed: June 12, 2008
    Date of Patent: July 22, 2014
    Inventor: Roy Arlington Jordan
  • Patent number: 8784862
    Abstract: The invention concerns oligosaccharides and polysaccharides as well as the use of these oligosaccharides and/or polysaccharides, which contain the sugar unit N-acylglucosamine or N-acylgalactosamine for the production of hemocompatible surfaces as well as methods for the hemocompatible coating of surfaces with said oligosaccharides and/or polysaccharides, which imitate the common biosynthetic precursor substance of heparin, heparan sulphates and chitosan. The invention further describes methods for producing said oligosaccharides and/or polysaccharides and discloses various possibilities of using hemocompatibly coated surfaces. The invention relates particularly to the use of said oligosaccharides and/or polysaccharides on stents with at least one according to invention deposited hemocompatible coating, which contains an antiproliferative, antiinflammatory and/or antithrombotic active agent, methods for the preparation of said stents as well as the use of said stents for the prevention of restenosis.
    Type: Grant
    Filed: June 30, 2010
    Date of Patent: July 22, 2014
    Assignee: Hemoteq AG
    Inventors: Roland Horres, Marita Katharina Linssen, Michael Hoffmann, Erika Hoffmann, Donate DiBiase, Volker Faust
  • Patent number: 8778868
    Abstract: The present invention relates to a stabilizer composition comprising an amino acid, and a sugar wherein all compounds are chemically defined; to a vaccine composition comprising such a stabilizer composition and a biological molecule and/or a micro-organism; to a method for preparing a pharmaceutical composition comprising admixing such a stabilizer composition with a biological molecule and/or a micro-organism; to the use of such a stabilizer composition, and of vaccines prepared therewith.
    Type: Grant
    Filed: March 7, 2006
    Date of Patent: July 15, 2014
    Assignee: Intervet International B.V.
    Inventors: Petrus Theodorus Johannes Andries van Gelder, Arnoldus Theodorus Petrus Loermans, Mathias Arnold Maassen
  • Patent number: 8741853
    Abstract: The instant invention constitutes an unique subject matter as a whole which has four individual aspects: (1) a class of chiral, non-racemic, synthetic carnitinoid analog carrier molecules which constitute biocompatible transport compounds not found in nature; (2) a subsequently formed, mitochondria-targeting, coupled antioxidant-carrier complex comprising an antioxidant reversibly attached to and releasable from the synthetic carrier molecule; (3) a method for introducing a biologically active antioxidant into the interior of mitochondria of a living cell for subsequent reaction with such reactive oxygen species may then be present; and (4) a system for delivering a biologically active antioxidant to the interior of mitochondria within a living cell.
    Type: Grant
    Filed: February 12, 2010
    Date of Patent: June 3, 2014
    Inventor: Kosta Steliou
  • Patent number: 8741967
    Abstract: The present invention is directed to unsaturated sphingosine compounds which are useful as therapeutic agents for the treatment of cancer and for the treatment of other diseases including diabetes and infection with intracellular bacteria. This invention is also directed to methods of using the compounds and pharmaceutical compositions comprising the compounds in treating these diseases.
    Type: Grant
    Filed: December 12, 2008
    Date of Patent: June 3, 2014
    Assignees: Children's Hospital & Research Center at Oakland, Research Foundation of the City University of New York
    Inventors: Julie D. Saba, Henrik Fyrst, Robert Bittman
  • Patent number: 8653146
    Abstract: The present application relates to a method for treating or preventing Th17 inflammatory disease mediated with IL-6 or IL-17 by administration of medication which inhibits vascular endothelial growth factor receptors, and a pharmaceutical composition therefor.
    Type: Grant
    Filed: May 20, 2010
    Date of Patent: February 18, 2014
    Assignee: Postech Academy-Industry Foundation
    Inventors: Yoon Keun Kim, Yong Song Gho, Yu Sun Kim
  • Patent number: 8642636
    Abstract: This invention provides for dimeric1-arylpyrazole compounds, of formulas (I), (II), and (III): or salts thereof, and the use of these compounds against ectoparasites such as insects, arthropods and acarina. The resulting compounds may be used in veterinary formulations such as, for example, spot-on and pour-on formulations, which may be used for treatment, controlling and preventing of parasitic infections in warm-blooded animals and birds.
    Type: Grant
    Filed: November 18, 2009
    Date of Patent: February 4, 2014
    Assignee: Merial Limited
    Inventor: Charles Q. Meng
  • Patent number: 8637323
    Abstract: Nitric oxide probes including a compound represented by Formula, I, II, III, IV, V, VI or a combination thereof are provided. Methods of using these nitric oxide probes to detect nitric oxide are also provided.
    Type: Grant
    Filed: October 4, 2012
    Date of Patent: January 28, 2014
    Assignee: Board of Regents, The University of Texas System
    Inventors: Eric V. Anslyn, Youjun Yang, Michelle M. Adams
  • Patent number: 8623924
    Abstract: Compositions and methods useful for inducing an increase in fatty acid oxidation or mitochondrial biogenesis, reducing weight gain, inducing weight loss, or increasing Sirt1, Sirt3, or AMPK activity are provided herein. Such compositions can contain synergizing amounts of a sirtuin-pathway activators, including but not limited to resveratrol, in combination with beta-hydroxymethylbutyrate (HMB), keto isocaproic acid (KIC), leucine, or combinations of HMB, KIC and leucine.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: January 7, 2014
    Assignee: Nusirt Sciences, Inc.
    Inventors: Michael Zemel, E. Douglas Grindstaff, II, Antje Bruckbauer
  • Patent number: 8623409
    Abstract: An oral clonidine dosage unit providing a twenty-four hour extended release profile following a single dose administration is provided. The dosage unit comprises a pharmaceutically effective amount of a coated complex comprising clonidine bound to a cationic exchange resin, which is characterized by a twenty-four hour release profile with a single peak, wherein said oral clonidine dosage unit provides a therapeutically effective plasma concentration for at least about 70%, or at least 85% of the twenty-four hour period following the single dose administration. Both liquid and solid formulations are provided, as are methods of treating a patient by a single administration of a formulation of the invention so as to achieve a therapeutic effect for 24-hours.
    Type: Grant
    Filed: October 20, 2010
    Date of Patent: January 7, 2014
    Assignee: Tris Pharma Inc.
    Inventors: Ketan Mehta, Yu-Hsing Tu
  • Patent number: 8604007
    Abstract: Disclosed herein are crystalline compounds of formula (I) wherein A+ represents a hydroxylated aliphatic ammonium species; and X and Y independently represent leaving groups.
    Type: Grant
    Filed: April 4, 2008
    Date of Patent: December 10, 2013
    Assignee: Ziopharm Oncology, Inc.
    Inventors: John C. Amedio, Jr., Barbara P. Wallner, Philip B. Komarnitsky
  • Patent number: 8580861
    Abstract: The present invention provides preservative compositions suitable for replacing, partially or in totality, conventional preservatives in skin care and hygiene cosmetic or pharmaceutical products. The preservative formulations include an organic carboxylic acid present in a concentration from about 0.01 to about 30 wt./wt. % of the formulation, an alcohol present in a concentration from about 0.01 to about 60 wt./wt. % of the formulation. The formulations include an inorganic salt present in a concentration from about 0.01 to about 80 wt./wt. % of the formulation, and a chelating agent present in a concentration from about 0.01 to about 20 wt./wt. % of the formulation.
    Type: Grant
    Filed: August 15, 2008
    Date of Patent: November 12, 2013
    Assignee: Pibed Limited
    Inventors: Pierre Bruno Grascha, Mylene Battut
  • Patent number: 8575222
    Abstract: The present invention relates to the use of nitric oxide releasing compounds for retarding or reversing muscular dystrophies such as Duchenne and Becker dystrophies.
    Type: Grant
    Filed: January 23, 2007
    Date of Patent: November 5, 2013
    Assignee: Nicox S.A.
    Inventors: Emilio Clementi, Giulio Cossu, Silvia Brunelli, Ennio Ongini
  • Patent number: 8563011
    Abstract: The use of low molecular weight amino alcohols in ophthalmic compositions is described. These compounds have been found to enhance the efficacy of anti-microbial preservatives.
    Type: Grant
    Filed: January 30, 2006
    Date of Patent: October 22, 2013
    Assignee: Alcon Research, Ltd.
    Inventor: Bahram Asgharian
  • Patent number: 8557873
    Abstract: The invention provides a method for treating septic shock or endotoxemia, which comprises administering to a subject a therapeutically effective amount of a pharmaceutical composition comprising formula I, II, III or IV and their salt, ester or solvate thereof.
    Type: Grant
    Filed: June 14, 2010
    Date of Patent: October 15, 2013
    Inventor: Soo-Ray Wang
  • Patent number: 8552068
    Abstract: Gaseous nitric oxide (NO) can be delivered to a mammal for prophylactic or therapeutic purposes using a composition capable of delivering NO, comprising a compound capable of forming a reversible bond or association with NO. Methods for the manufacture and use of said composition are disclosed.
    Type: Grant
    Filed: September 14, 2005
    Date of Patent: October 8, 2013
    Inventors: Per Agvald, Dag Linnarsson, Christofer Adding, Lars Gustafsson, Kristofer Nilsson
  • Patent number: 8541628
    Abstract: Cationic lipids having a derivatized quaternary ammonium head group that provide improved cell targeting ability and enhanced transfective efficacy for introducing molecules into cells are provided.
    Type: Grant
    Filed: December 30, 2003
    Date of Patent: September 24, 2013
    Assignee: Vical Incorporated
    Inventor: Carl J Wheeler
  • Patent number: 8524214
    Abstract: Polyal-Drug conjugates comprising a variable rate-releasing linker are described along with methods of making such conjugates. Uses for such Polyal-Drug conjugates is also described.
    Type: Grant
    Filed: May 27, 2010
    Date of Patent: September 3, 2013
    Assignee: Mersana Therapeutics, Inc.
    Inventors: Aleksandr Yurkovetskiy, Mao Yin, Gui Liu, Laura C. Akullian, John J. Kane, Cheri A. Stevenson, Charles E. Hammond, Russell C. Petter, John H. Van Duzer, Timothy B. Lowinger
  • Publication number: 20130109570
    Abstract: Fumigant compositions including hexafluoropropene or 1,1,3,3,3-pentafluoropropene, and methods of preparing such compositions, are provided herein. The fumigant compositions may be suitable for use as soil fumigant compositions and structural fumigant compositions against a variety of undesirable species such as weeds, nematodes, pathogens, animals and insects. The fumigant compositions also have low toxicity and low Global Warming Potential.
    Type: Application
    Filed: October 15, 2012
    Publication date: May 2, 2013
  • Patent number: 8426472
    Abstract: The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.
    Type: Grant
    Filed: October 28, 2011
    Date of Patent: April 23, 2013
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
  • Patent number: 8410177
    Abstract: A compound has Formula VIII where, X is —C(O)R, —C(O)OR, —CN, —NO2, —S(O)2R?, —P(O)(OR)2; each R is individually H, alkyl, or alkenyl; R? is alkyl or akenyl; R1 is aryl, alkenyl, arylalkenyl, heterocyclyl, or heteroaryl; and R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11 are individually H, alkoxy, or hydroxy. In some cases, X is NO2. Pharmaceutical compositions of the compound of Formula VIII with a pharmaceutically acceptable carrier may be prepared. The compounds may be used for inhibition of cyclooxygenase-2.
    Type: Grant
    Filed: March 4, 2010
    Date of Patent: April 2, 2013
    Assignee: Indian Institute of Technology Bombay
    Inventors: Irishi N. N. Namboothiri, Narasimham Ayyagari, Deena Jose
  • Patent number: 8377475
    Abstract: In one aspect, the present invention features a tablet including: (i) a first drug layer including naproxen; (ii) a second drug layer including a decongestant (e.g., pseudoephedrine) wherein said second drug layer is a sustained release layer adapted to deliver a therapeutically effective amount of pseudoephedrine for a period of at least twelve hours; and (iii) a barrier layer that does not include naproxen, wherein the barrier layer is in contact with the first drug layer; and (iv) a third drug layer including cetirizine, wherein the third drug layer is in contact with the barrier layer and is not in contact with the first drug layer.
    Type: Grant
    Filed: January 4, 2010
    Date of Patent: February 19, 2013
    Assignee: McNeil-PPC, Inc.
    Inventors: Satish Kamath, Indukumar G. Shah, Michael Nichols, Dinesh Patel
  • Patent number: 8367645
    Abstract: The invention relates to a composition that includes a first agent selected including an agent that possesses anti-inflammatory activity or acetaminophen, phenacetin, tramadol and the like; a second agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an adenosine 5-monophosphate-activated Protein kinase (AMPK) activator; a third agent that possesses or maintains serotonin activity.
    Type: Grant
    Filed: May 18, 2009
    Date of Patent: February 5, 2013
    Inventor: Chien-Hung Chen
  • Patent number: 8324188
    Abstract: A method to determine the utility of small molecules as functional replacements (mimetics) for protein receptor ligands is described. The method uses cellular biological assays on a systematic array of compounds, comprising known protein receptor ligands and other biologically active molecules to determine if a proposed small molecule is a functional equivalent of a receptor ligand, having therapeutic utility as a pharmaceutically relevant and useful agent either alone or in combination with other molecules. Furthermore, the invention provides for a method for the treatment of cancer comprising administering a combination of ET-18-O-CH3 and an anti-cancer agent.
    Type: Grant
    Filed: November 9, 2007
    Date of Patent: December 4, 2012
    Inventors: Vladimir Khazak, Lutz Weber
  • Patent number: 8318705
    Abstract: The invention relates to nitroso derivatives including carboxylic acid and phosphoric acid esters of hydroxy nitroso compounds that donate nitroxyl (HNO) under physiological conditions. The compounds and compositions of the invention are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure, ischemia/reperfusion injury and cancer.
    Type: Grant
    Filed: May 7, 2009
    Date of Patent: November 27, 2012
    Assignee: Cardioxyl Pharmaceuticals, Inc.
    Inventors: Lisa M. Frost, Stephen M. Courtney, Frederick A. Brookfield, Vincent J. Kalish
  • Patent number: 8299124
    Abstract: An aqueous eye drop comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof and an organic amine (for example, aminoethylsulfonic acid or trometamol) or a salt thereof is useful as an eye drop for once a day administration for treating inflammatory diseases of the external segment or the anterior segment of the eyes, since such aqueous eye drop can maintain a therapeutically effective concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid in anterior aqueous humor for at least 24 hours by once a day administration.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: October 30, 2012
    Assignee: Senju Pharmaceutical Co., Ltd.
    Inventors: Shirou Sawa, Tomoko Fujimoto
  • Publication number: 20120237615
    Abstract: The present invention provides O-nitro compounds, pharmaceutical compositions of O-nitro compounds and methods of using O-nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Application
    Filed: May 30, 2012
    Publication date: September 20, 2012
    Inventors: Mark D. Bednarski, Lynn M. Oehler, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
  • Patent number: 8252330
    Abstract: In one aspect, the present invention features a tablet including a first drug layer and a second drug layer, wherein: (i) the first drug layer includes first drug particles including naproxen and third drug particles including cetirizine, where the first drug particles and/or the third drug particles are coated with an immediate release coating; and (ii) the second drug layer including pseudoephedrine, wherein said second drug layer is a sustained release layer adapted to deliver a therapeutically effective amount of pseudoephedrine for a period of at least twelve hours.
    Type: Grant
    Filed: January 4, 2010
    Date of Patent: August 28, 2012
    Assignee: McNEIL-PPC, Inc.
    Inventors: Satish Kamath, Michael Nichols
  • Publication number: 20120213861
    Abstract: Rodenticide compositions that include 2-chloropentafluoropropene, and methods of using such rodenticide compositions, are provided. The rodenticide compositions can be used as fumigants in space fumigation applications. In some examples, the rodenticide compositions can be used as drop-in replacements for methyl bromide in existing rodenticide compositions and methods of exterminating rodents using methyl bromide.
    Type: Application
    Filed: February 22, 2011
    Publication date: August 23, 2012
    Inventors: Andrew Joseph Poss, Rajiv Ratna Singh, David Nalewajek, Cheryl Cantlon